251 related articles for article (PubMed ID: 30233802)
1. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: design of a double-blind, randomised, placebo-controlled phase II trial.
Maher TM; Corte TJ; Fischer A; Kreuter M; Lederer DJ; Molina-Molina M; Axmann J; Kirchgaessler KU; Cottin V
BMJ Open Respir Res; 2018; 5(1):e000289. PubMed ID: 30233802
[TBL] [Abstract][Full Text] [Related]
2. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.
Maher TM; Corte TJ; Fischer A; Kreuter M; Lederer DJ; Molina-Molina M; Axmann J; Kirchgaessler KU; Samara K; Gilberg F; Cottin V
Lancet Respir Med; 2020 Feb; 8(2):147-157. PubMed ID: 31578169
[TBL] [Abstract][Full Text] [Related]
3. Pirfenidone in Unclassifiable Interstitial Lung Disease: A Subgroup Analysis by Concomitant Mycophenolate Mofetil and/or Previous Corticosteroid Use.
Kreuter M; Maher TM; Corte TJ; Molina-Molina M; Axmann J; Gilberg F; Kirchgaessler KU; Cottin V
Adv Ther; 2022 Feb; 39(2):1081-1095. PubMed ID: 34936057
[TBL] [Abstract][Full Text] [Related]
4. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
Wells AU; Flaherty KR; Brown KK; Inoue Y; Devaraj A; Richeldi L; Moua T; Crestani B; Wuyts WA; Stowasser S; Quaresma M; Goeldner RG; Schlenker-Herceg R; Kolb M;
Lancet Respir Med; 2020 May; 8(5):453-460. PubMed ID: 32145830
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Pirfenidone vs. Placebo in Unclassifiable Interstitial Lung Disease, by Surgical Lung Biopsy Status: Data From a
Molina-Molina M; Kreuter M; Cottin V; Corte TJ; Gilberg F; Kirchgaessler KU; Axmann J; Maher TM
Front Med (Lausanne); 2022; 9():897102. PubMed ID: 35783648
[TBL] [Abstract][Full Text] [Related]
6. Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study.
Solomon JJ; Danoff SK; Woodhead FA; Hurwitz S; Maurer R; Glaspole I; Dellaripa PF; Gooptu B; Vassallo R; Cox PG; Flaherty KR; Adamali HI; Gibbons MA; Troy L; Forrest IA; Lasky JA; Spencer LG; Golden J; Scholand MB; Chaudhuri N; Perrella MA; Lynch DA; Chambers DC; Kolb M; Spino C; Raghu G; Goldberg HJ; Rosas IO;
Lancet Respir Med; 2023 Jan; 11(1):87-96. PubMed ID: 36075242
[TBL] [Abstract][Full Text] [Related]
7. Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with progressive pulmonary fibrosis (FIBRONEER-ILD).
Maher TM; Assassi S; Azuma A; Cottin V; Hoffmann-Vold AM; Kreuter M; Oldham JM; Richeldi L; Valenzuela C; Wijsenbeek MS; Coeck C; Schlecker C; Voss F; Wachtlin D; Martinez FJ
BMJ Open Respir Res; 2023 Sep; 10(1):. PubMed ID: 37709661
[TBL] [Abstract][Full Text] [Related]
8. Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease.
Flaherty KR; Brown KK; Wells AU; Clerisme-Beaty E; Collard HR; Cottin V; Devaraj A; Inoue Y; Le Maulf F; Richeldi L; Schmidt H; Walsh S; Mezzanotte W; Schlenker-Herceg R
BMJ Open Respir Res; 2017; 4(1):e000212. PubMed ID: 29018526
[TBL] [Abstract][Full Text] [Related]
9. Autoimmune Progressive Fibrosing Interstitial Lung Disease: Predictors of Fast Decline.
Nagy A; Nagy T; Kolonics-Farkas AM; Eszes N; Vincze K; Barczi E; Tarnoki AD; Tarnoki DL; Nagy G; Kiss E; Maurovich-Horvat P; Bohacs A; Müller V
Front Pharmacol; 2021; 12():778649. PubMed ID: 35002713
[TBL] [Abstract][Full Text] [Related]
10. Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial.
Behr J; Bendstrup E; Crestani B; Günther A; Olschewski H; Sköld CM; Wells A; Wuyts W; Koschel D; Kreuter M; Wallaert B; Lin CY; Beck J; Albera C
Lancet Respir Med; 2016 Jun; 4(6):445-53. PubMed ID: 27161257
[TBL] [Abstract][Full Text] [Related]
11. CC-90001, a c-Jun N-terminal kinase (JNK) inhibitor, in patients with pulmonary fibrosis: design of a phase 2, randomised, placebo-controlled trial.
Popmihajlov Z; Sutherland DJ; Horan GS; Ghosh A; Lynch DA; Noble PW; Richeldi L; Reiss TF; Greenberg S
BMJ Open Respir Res; 2022 Jan; 9(1):. PubMed ID: 35058236
[TBL] [Abstract][Full Text] [Related]
12. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.
Feng H; Zhao Y; Li Z; Kang J
Ther Adv Respir Dis; 2020; 14():1753466620963015. PubMed ID: 33070705
[TBL] [Abstract][Full Text] [Related]
13. The Design and Rationale of the Trail1 Trial: A Randomized Double-Blind Phase 2 Clinical Trial of Pirfenidone in Rheumatoid Arthritis-Associated Interstitial Lung Disease.
Solomon JJ; Danoff SK; Goldberg HJ; Woodhead F; Kolb M; Chambers DC; DiFranco D; Spino C; Haynes-Harp S; Hurwitz S; Peters EB; Dellaripa PF; Rosas IO;
Adv Ther; 2019 Nov; 36(11):3279-3287. PubMed ID: 31515704
[TBL] [Abstract][Full Text] [Related]
14. Design and rationale of a randomised, double-blind trial of the efficacy and safety of pirfenidone in patients with fibrotic hypersensitivity pneumonitis.
Fernández Pérez ER; Crooks JL; Swigris JJ; Solomon JJ; Mohning MP; Huie TJ; Koslow M; Lynch DA; Groshong SD; Fier K
ERJ Open Res; 2021 Apr; 7(2):. PubMed ID: 34109243
[TBL] [Abstract][Full Text] [Related]
15. Cyclophosphamide for connective tissue disease-associated interstitial lung disease.
Barnes H; Holland AE; Westall GP; Goh NS; Glaspole IN
Cochrane Database Syst Rev; 2018 Jan; 1(1):CD010908. PubMed ID: 29297205
[TBL] [Abstract][Full Text] [Related]
16. Clinical and Functional Characteristics of Patients with Unclassifiable Interstitial Lung Disease (uILD): Long-Term Follow-Up Data from European IPF Registry (eurIPFreg).
Krauss E; El-Guelai M; Pons-Kuehnemann J; Dartsch RC; Tello S; Korfei M; Mahavadi P; Breithecker A; Fink L; Stoehr M; Majeed RW; Seeger W; Crestani B; Guenther A
J Clin Med; 2020 Aug; 9(8):. PubMed ID: 32756496
[TBL] [Abstract][Full Text] [Related]
17. Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases.
Torrisi SE; Kahn N; Wälscher J; Sarmand N; Polke M; Lars K; Eichinger M; Heussel CP; Palmucci S; Sambataro FM; Sambataro G; Sambataro D; Vancheri C; Kreuter M
BMC Pulm Med; 2019 Nov; 19(1):213. PubMed ID: 31718637
[TBL] [Abstract][Full Text] [Related]
18. [Antifibrotic therapy - new approvals for non-IPF interstitial lung diseases].
Markart P; Drakopanagiotakis F; Wygrecka M
Dtsch Med Wochenschr; 2021 Feb; 146(3):181-184. PubMed ID: 33513653
[TBL] [Abstract][Full Text] [Related]
19. Exploring efficacy and safety of oral Pirfenidone for progressive, non-IPF lung fibrosis (RELIEF) - a randomized, double-blind, placebo-controlled, parallel group, multi-center, phase II trial.
Behr J; Neuser P; Prasse A; Kreuter M; Rabe K; Schade-Brittinger C; Wagner J; Günther A
BMC Pulm Med; 2017 Sep; 17(1):122. PubMed ID: 28877715
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
